Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 30 PAGES: 40

More Info
									        Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT Analysis
                                     Review
        Reference Code: GDPH127065FSA                                                                                         Publication Date: APR 2013

          Kronprinsesse Marthas Plass 1, P.O.
                                                             Phone              +47 2 3010960                   Revenue          109.50 (million NOK)
          Box 1477
          Oslo                                               Fax                +47 2 3010970                   Net Profit       -66.88 (million NOK)
          0116                                               Website            www.bionorpharma.com            Employees        18
                                                                                BIONOR [Oslo         Stock                       Pharmaceuticals           &
          Norway                                             Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       Bionor Pharma ASA (Bionor Pharma), formerly Nutri Pharma ASA, is a Norway-based biotechnology company. It is a
       development company involved in the development of vaccines for the treatment and prevention of lifestyle-related diseases. The
       company develops patented products with proven health benefits and many of its products are used in 40 clinical and pre-clinical
       trials. It also develops modified peptide-based vaccines targeting rapidly mutating viruses. The company also manages a portfolio
       of out-licensed soy-based weight management and nutritional supplements, which include Nutrilett products (Nutrilett and
       NutriPro) and Nutri5 products.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Bionor Pharma ASA, SWOT Analysis
         David McAdam                        Chief Executive Officer                  Strengths                              Weaknesses
         Lars H. Hoie, Ph.D.                 Chairman
                                                                                      Broad Product Portfolio                Business Concentration:
         Bjorn Fuglaas                       Director                                                                        Europe
                                                                                      Strong R&D Activities
         Marianne Furru                      Director
         Steen Kroyer                        Deputy Chairman of the
                                             Board                                    Opportunities                          Threats
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Changing Demographics                  Uncertain R&D Outcomes

       Share Data                                                                     Market Potential – Infectious          Intense Competition
                                                                                      Diseases
         Bionor Pharma ASA
        Share Price (NOK) as on 22-Apr-                                  2.68
        2013                                                                         Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
        EPS (NOK)                                                       -0.37
        Market Cap (million NOK)                                         484
        Enterprise Value (million NOK)                                   375
        Shares Outstanding (million)                                     181
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 01, 2013         Bionor Pharma Appoints Synne Roine As CFO
                                                                                      Feb 15, 2013         Bionor Pharma Reports 2012 Results
                                                                                      Jan 29, 2013         Bionor Pharma Names Anker Lundemose As
                                                                                                           CEO
                                                                                      Dec 06, 2012         Bionor Pharma Reports Q3 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT                                                                     Reference Code: GDPH127065FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Bionor Pharma ASA - Key Facts ........................................................................................................................................................ 5
       Bionor Pharma ASA - Key Employees ............................................................................................................................................... 6
       Bionor Pharma ASA - Key Employee Biographies ............................................................................................................................. 7
       Bionor Pharma ASA - Major Products and Services .......................................................................................................................... 8
       Bionor Pharma ASA - Pharmaceutical Pipeline Products Data .......................................................................................................... 9
          Bionor Pharma ASA, Pipeline Products by Therapy Area............................................................................................................... 9
          Bionor Pharma ASA, Pipeline Products by Development Phase .................................................................................................. 10
       Bionor Pharma ASA - History ........................................................................................................................................................... 12
       Bionor Pharma ASA - Company Statement...................................................................................................................................... 14
       Bionor Pharma ASA - Locations And Subsidiaries ........................................................................................................................... 16
          Head Office ................................................................................................................................................................................... 16
          Other Locations & Subsidiaries ..................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       Bionor Pharma ASA - Business Description ..................................................................................................................................... 17
       Bionor Pharma ASA - SWOT Analysis ............................................................................................................................................. 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          Bionor Pharma ASA - Strengths ................................................................................................................................................... 18
             Strength - Broad Product Portfolio ............................................................................................................................................ 18
             Strength - Strong R&D Activities ............................................................................................................................................... 18
             Strength - Proprietary Technology Platform .............................................................................................................................. 19
          Bionor Pharma ASA - Weaknesses .............................................................................................................................................. 19
             Weakness - Business Concentration: Europe ........................................................................................................................... 19
          Bionor Pharma ASA - Opportunities ............................................................................................................................................. 19
             Opportunity - Changing Demographics ..................................................................................................................................... 19
             Opportunity - Market Potential – Infectious Diseases ................................................................................................................ 19
             Opportunity - Partnerships and Collaborations.......................................................................................................................... 20
          Bionor Pharma ASA - Threats ...................................................................................................................................................... 20
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
             Threat - Intense Competition ..................................................................................................................................................... 20
             Threat - Poor Publicity or Consumer Perception ....................................................................................................................... 20
       Bionor Pharma ASA - Key Competitors ............................................................................................................................................ 21
       Section 3 – Company Financial Ratios ............................................................................................................................................. 22
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 22
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 22
       Performance Chart ........................................................................................................................................................................... 24
       Financial Performance...................................................................................................................................................................... 24
       Financial Ratios - Interim Ratios....................................................................................................................................................... 25
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 26
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 27
          Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ............................................................ 27
          Bionor Pharma ASA, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ........................................................... 28


Bionor Pharma ASA (BIONOR) - Financial and Strategic SWOT                                                                                                    Reference Code: GDPH127065FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Bionor Pharma ASA, Recent Deals Summary.................................................................................................................................. 29
       Section 5 – Company’s Recent Developments ................................................................................................................................ 30
          Bionor Pharma ASA, Recent Developments................................................................................................................................. 30
             Mar 01, 2013: Bionor Pharma Appoints Synne Roine As CFO ...................................................................................
								
To top